LTR Pharma (ASX:LTP) Receivables Turnover : 0.00 (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. LTR Pharma's Revenue for the six months ended in Jun. 2023 was A$0.00 Mil. LTR Pharma's average Accounts Receivable for the six months ended in Jun. 2023 was A$0.00 Mil.

LTR Pharma Receivables Turnover Historical Data

The historical data trend for LTR Pharma's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Receivables Turnover Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Receivables Turnover

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
Receivables Turnover	-	-	-

Competitive Comparison of LTR Pharma's Receivables Turnover

For the Biotechnology subindustry, LTR Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where LTR Pharma's Receivables Turnover falls into.

LTR Pharma Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

LTR Pharma's Receivables Turnover for the fiscal year that ended in Jun. 2023 is calculated as

	Receivables Turnover (A: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Jun. 2023 )	/ (	(Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

LTR Pharma's Receivables Turnover for the quarter that ended in Jun. 2023 is calculated as

	Receivables Turnover (Q: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2023 )	/ (	(Accounts Receivable (Q: Jun. 2022 )	+	Accounts Receivable (Q: Jun. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

LTR Pharma (ASX:LTP) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

LTR Pharma Receivables Turnover Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines